Sound waves open brain barrier to attack deadly childhood tumor
NCT ID NCT05615623
First seen Apr 25, 2026 · Last updated Jun 20, 2026 · Updated 8 times
Summary
This early-stage trial tests whether focused ultrasound can safely open the blood-brain barrier in children with a deadly brain tumor called DIPG, allowing the chemotherapy drug doxorubicin to reach the tumor. Ten children aged 5 to 18 will receive the treatment after finishing radiation. The main goal is to check for side effects and see if the barrier opens as expected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sunnybrook Research Institute
Toronto, Ontario, M4N 3M5, Canada
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Doxorubicin (a chemotherapy drug) combined with Exablate focused ultrasound device to temporarily open the blood-brain barrier
What this could lead to
If it works, this could point toward a new way to deliver chemotherapy directly to hard-to-treat brain tumors in children.
What could go wrong
This is a very early, small trial (only 10 children) focused on safety. It may not show benefit, and there are risks from the ultrasound procedure and chemotherapy side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.